Tevogen

📰 globenewswire.com/news-release/2… Sharing his thoughts on the donation, William Keane, Vice President of Strategic Initiatives, stated, “As someone who served the Warren community for 35 years, including nearly a decade as Chief of Police, I know how essential it is for law-enforcement agencies to have the tools and support required to keep residents safe. Dr. Saadi’s donation reflects his deep commitment to this town and to the officers who protect it. Tevogen has spent the past year earning recognition for its disciplined execution, expanding footprint, and the significant multi-billion-dollar potential of its long-term vision. What strikes me most is that this ambition has always been matched by a sense of responsibility to the communities we serve. Today’s contribution reflects that same principle of building for the future while ensuring that those on the front lines have what they need right now. I’m proud to be part of an organization whose leadership invests not only in transformative science and technology, but also in the safety and wellbeing of the place we call home.” $TVGN @Tevogen @WarrenTwpNJ @warren_policenj #affordable #accessible #celltherapy

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… Warren-based Tevogen is a clinical-stage specialty immunotherapy biotech company pioneering off-the-shelf T cell therapeutics for infectious diseases, oncology, and neurology. Founded by Dr. Ryan Saadi, the company leverages its patented ExacTcell platform to target virus-infected and cancerous cells. Tevogen's pipeline includes therapies for SARS-CoV-2 in high-risk patients, Long COVID and multiple oncology indications supported by its Al-driven PredicTcell platform. The company projects nearly $1 billion in revenue in its launch year for specialty care, with cumulative 5-year forecasts reaching $18 billion-$22 billion. Tevogen is also expanding its footprint here in New Jersey with a newly leased 17,428-square-foot manufacturing facility and a new corporate headquarters that more than doubles its previous space, centralizing R&D, regulatory and Tevogen.AI operations. Saadi personally contributed $500,000 toward the build-out and first-year operating costs. He said, "This contribution is about belief in Tevogen's mission, in the remarkable people who bring that mission to life, and in the future we are building together." $TVGN @NJBIZ #affordable #accessible #celltherapy #AIinMedicine #CapitalEfficiency